At the archive date, VERTEX PHARMACEUTICALS INC / MA was expected to release its Q3 2026 10-Q filing on November 2, 2026. Last quarter: Vertex Pharmaceuticals reported a 12.5% revenue increase in Q2 FY2026 driven by its cystic fibrosis franchise and strong early sales of new therapies CASGEVY and JOURNAVX, while announcing a $10 billion acquisition of Crinetics Pharmaceuticals to expand its pipeline.
EPS Estimate
$4.89
Revenue Estimate
$3.48B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the VRTX page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
ALYFTREK secured reimbursement in four additional countries, including Spain, bringing the total to 25 countries, and a letter of intent was signed with the Pan-Canadian Pharmaceutical Alliance for reimbursement in Canada.
CASGEVY product revenues surged 151% YoY to $76.4 million, and the FDA approved its use in children aged 2+ with SCD or TDT, making approximately 5,500 additional patients eligible.
JOURNAVX prescriptions reached 900,000 in the first half of 2026, with reimbursement coverage now extending to approximately 260 million lives after agreements with major Medicare Part D plans.
Revenue
$3.33B
+12.45% YoY
EPS (Diluted)
$4.31
+8.02% YoY
Operating Income
$1.25B
+8.32% YoY
Add VRTX to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.